10 Best Beaten Down Growth Stocks to Buy According to Analysts

2. ​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Price: $51.86

52-Week Range: 51.57 – 73.51

FWD EPS Growth: 37.26%

Number of Hedge Fund Holders: 58

Analyst Upside Potential: 82.22%

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. On October 19, Sean Laaman from Morgan Stanley maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a price target of $104.

​The analyst likes the company’s market position and growth potential. He noted that the company’s international expansion of Voxzogo has shown revenue growth. He expects the management to continue expanding Voxzogo in other countries and noted it to be one of the key drivers for the company.

​Laaman also noted the promising pipeline of the company. He highlighted BMN 351 and BMN 333 as potential catalysts for future growth. He noted that a strong pipeline topped by BioMarin Pharmaceutical Inc. ‘s (NASDAQ:BMRN) ability to maintain its leadership in skeletal dysplasias despite the challenges further strengthens its position in the market.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is an international biopharmaceutical company that develops and commercializes targeted therapies addressing the root causes of rare genetic conditions.